Logo Logo
Eine Ebene nach oben
Exportieren als [RSS feed] RSS 1.0 [RSS2 feed] RSS 2.0
Gruppiert nach: Dokumententyp | Veröffentlichungsdatum
Anzahl der Publikationen: 9

Zeitschriftenartikel

Stahler, A.; Heinemann, V.; Clemens, G.; Crispin, A.; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P. (2016): Prevalence and influence on outcome of Neuregulin- (NRG1), HER2/neu- and HER3-expression in patients with metastatic colorectal cancer (mCRC) treated with irinotecan-based first-line regimens (FUFIRI vs. mIROX) in the FIRE 1-trial. In: Oncology Research and Treatment, Bd. 39: S. 72

Stahler, A.; Heinemann, V.; Giessen-Jung, C.; Crispin, Alexander; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P. (2015): Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial). In: International Journal of Cancer, Bd. 138, Nr. 3: S. 739-746

Giessen, C.; Fischer von Weikersthal, L.; Laubender, Rüdiger P.; Stintzing, S.; Modest, D. P.; Schalhorn, A.; Schulz, C. und Heinemann, V. (2013): Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial. In: British Journal of Cancer BJC, Bd. 109, Nr. 6: S. 1428-1436

Giessen, C.; Laubender, Rüdiger P.; Fischer von Weikersthal, L.; Schalhorn, A.; Modest, D. P.; Stintzing, S.; Haas, M.; Mansmann, Ulrich und Heinemann, V. (2013): Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan-based randomized first-line trial. In: Cancer Science, Bd. 104, Nr. 6: S. 718-724

Giessen, C.; Stintzing, S.; Laubender, Rüdiger P.; Ankerst, Donna Pauler; Schulz, C.; Moosmann, N.; Modest, D. P.; Schalhorn, A.; Fischer von Weikersthal, L. und Heinemann, V. (2011): Analysis for Prognostic Factors of 60-day Mortality: Evaluation of an Irinotecan-Based Phase III Trial Performed in the First-Line Treatment of Metastatic Colorectal Cancer. In: Clinical Colorectal Cancer, Bd. 10, Nr. 4: S. 317-324

Wilkowski, R.; Pachmann, S.; Schymura, B.; Dellian, M.; Schalhorn, A. und Dühmke, Eckhart (2005): A new concurrent chemotherapy with vinorelbine and mitomycin C in combination with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. In: Onkologie, Nr. 10: S. 491-495 [PDF, 90kB]

Stemmler, J.; Stieber, P.; Szymala, A. M.; Schalhorn, A.; Schermuly, M. M.; Wilkowski, R.; Helmberger, T.; Lamerz, Rolf; Stoffregen, C.; Niebler, K.; Garbrecht, M. und Heinemann, Volker (2003): Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? In: Onkologie, Nr. 5: S. 462-467 [PDF, 115kB]

Stemmler, Joachim; Heinemann, Volker und Schalhorn, A. (2002): Capecitabine as second-line treatment for metastatic cholangiocarcinoma: A report of two cases. In: Onkologie, Nr. 2: S. 182-184 [PDF, 49kB]

Stemmler, J.; Weise, A.; Hacker, U.; Heinemann, Volker und Schalhorn, A. (2002): Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure. In: Onkologie, Nr. 1: S. 60-63 [PDF, 59kB]

Diese Liste wurde am Sat Mar 16 22:38:15 2024 CET erstellt.